Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Crysler

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligandsJuan Jose Marugan, Kristin D Haslow, Carl Crysler
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitorsLily Lee, Kevin D Kreutter, Wenxi Pan, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2011
Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonistsXuqing Zhang, Heather Hufnagel, Cuifen Hou, et al.
European Journal of Medicinal Chemistry|May 16, 2006
Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albuminPierre Raboisson, Carl L Manthey, Margery Chaikin, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2013
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonistsNalin L Subasinghe, James Lanter, Thomas Markotan, et al.
Biochemical Pharmacology|July 6, 2010
Potency variation of small-molecule chymase inhibitors across speciesJukka Kervinen, Carl Crysler, Shariff Bayoumy, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitorsBruce Tomczuk, Tianbao Lu, Richard M Soll, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonistsXuqing Zhang, Heather Hufnagel, Thomas Markotan, et al.
Journal of Medicinal Chemistry|February 18, 2005
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular coreJuan José Marugán, Carl Manthey, Beth Anaclerio, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesisTianbao Lu, Thomas Markotan, Frank Coppo, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|September 11, 2004
Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligandsJuan Jose Marugan, Kristin D Haslow, Carl Crysler
Bioorganic & Medicinal Chemistry Letters|September 25, 2007
2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitorsLily Lee, Kevin D Kreutter, Wenxi Pan, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2011
Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonistsXuqing Zhang, Heather Hufnagel, Cuifen Hou, et al.
European Journal of Medicinal Chemistry|May 16, 2006
Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albuminPierre Raboisson, Carl L Manthey, Margery Chaikin, et al.
Bioorganic & Medicinal Chemistry Letters|January 9, 2013
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonistsNalin L Subasinghe, James Lanter, Thomas Markotan, et al.
Biochemical Pharmacology|July 6, 2010
Potency variation of small-molecule chymase inhibitors across speciesJukka Kervinen, Carl Crysler, Shariff Bayoumy, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Oxyguanidines: application to non-peptidic phenyl-based thrombin inhibitorsBruce Tomczuk, Tianbao Lu, Richard M Soll, et al.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonistsXuqing Zhang, Heather Hufnagel, Thomas Markotan, et al.
Journal of Medicinal Chemistry|February 18, 2005
Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular coreJuan José Marugán, Carl Manthey, Beth Anaclerio, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesisTianbao Lu, Thomas Markotan, Frank Coppo, et al.
Pageof 2